Search the Health Library
Get the facts on diseases, conditions, tests and procedures.
I Want To...
Find a Doctor
I Want To...
Find Research Faculty
Enter the last name, specialty or keyword for your search below.
Martin Gilbert Pomper, M.D., Ph.D.
Director, Nuclear Medicine and Molecular Imaging
Professor of Radiology and Radiological Science
Languages: English, French
Expertise: Diagnostic Radiology
Research Interests: Radiopharmacology; In Vivo and Molecular Imaging; Development of new radiotracers for PET and SPECT for cancer detection; Molecular imaging, particularly of central nervous system processes and cancer; Oncology; Translational Molecular Imaging ...read more
Request an Appointment
The Johns Hopkins Hospital (Main Entrance)
1800 Orleans St.
Baltimore, MD 21287 map
Johns Hopkins Outpatient Center
601 N. Caroline St.
Baltimore, MD 21287 map
Johns Hopkins Bayview Medical Center
Appointment Phone: 410-550-2948
4940 Eastern Avenue
Baltimore, MD 21224 map
Contact for Research Inquiries
Cancer Research Building 2
1550 Orleans Street
Baltimore, MD 21231 map
Dr. Martin Pomper is a Professor in the Johns Hopkins Medicine Department of Radiology and Radiological Science. Dr. Pomper is the Director of Nuclear Medicine and Molecular Imaging. He is also a Professor of Oncology and Radiation Oncology and Molecular Radiation Services. He is an internationally recognized leader in molecular imaging research and develops and implements new imaging agents that target cancer and brain disorders.
He is the inaugural recipient of the William R. Brody Professor of Radiology, a professorship designated for a radiologist physician scientist who excels in translational innovation in imaging.
Dr. Pomper is the Director of the Johns Hopkins Small Animal Imaging Resource and Associate Director of the In Vivo Cellular and Molecular Imaging Center, both funded by the National Cancer Institute to support molecular imaging research. He also co-directs the Kimmel Cancer Center's Cancer Molecular and Functional Imaging Program and the Cancer Functional Imaging Core.
Dr. Pomper received his undergraduate, graduate (organic chemistry) and medical degrees from the University of Illinois at Urbana-Champaign. His postgraduate medical training was at Johns Hopkins and included internship (Osler Medical Service), residencies (diagnostic radiology and nuclear medicine) and fellowship (neuroradiology). He is board certified in diagnostic radiology and nuclear medicine and has been on the faculty at Johns Hopkins since 1996.
Dr. Pomper’s interests are in the development of new radiopharmaceuticals, optical probes and techniques for molecular imaging of cancer and central nervous system disease. One area of focus is on imaging prostate cancer and the development of imaging and therapeutic agents targeting the prostate-specific membrane antigen (PSMA). He has numerous patents related to medical imaging, many of which have been licensed, as well as several imaging agents in clinical trials.
He is the immediate past President of the Society of Nuclear Medicines Molecular Imaging Center of Excellence and Editor-in-Chief of the journal Molecular Imaging.
- Director, Nuclear Medicine and Molecular Imaging
- Director, Johns Hopkins Small Animal Imaging Resource
- William R. Brody Professor of Radiology
- Associate Director, Johns Hopkins In Vivo Cellular and Molecular Imaging Center
- Co-director, Cancer Molecular and Functional Imaging, Sidney Kimmel Comprehensive Cancer Center
- Professor of Radiology and Radiological Science
- Joint Appointment in Psychiatry and Behavioral Sciences
- Professor of Oncology
- Professor of Pharmacology and Molecular Sciences
- Professor of Radiation Oncology and Molecular Radiation Sciences
Departments / Divisions
- MD; Medicine, University of Illinois College of Medicine at Urbana-Champaign (1990)
- Johns Hopkins University School of Medicine / Diagnostic Radiology and Nuclear Medicine (1995)
- Johns Hopkins University School of Medicine / Neuroradiology (1996)
- American Board of Nuclear Medicine / Nuclear Medicine (1995, 2005)
- American Board of Radiology / Diagnostic Radiology (1995)
Research & Publications
Dr. Pomper’s research projects in central nervous system imaging include using positron emission tomography (PET) and advanced magnetic resonance spectroscopy (MRS) techniques to uncover brain metabolic correlates of AIDS dementia; using PET to study molecular (neurotransmitter) and cellular abnormalities in patients with AIDS dementia; and the development of new radiopharmaceuticals for imaging nicotinic and glutamatergic neurotransmission as well as for imaging inflammation.
In oncology, he focuses on advanced magnetic resonance imaging (MRI) techniques, such as diffusion tensor and amide proton transfer imaging to study brain tumors. In addition, radiopharmaceutical and optical imaging agents are being developed to study prostate cancer, metastatic potential, infection, inflammation and to study the pharmacokinetics of chemotherapeutic agents in vivo. Molecular-genetic imaging of cancer is another priority.
His research group consists of chemists, physicists, molecular biologists and clinicians working together toward clinical molecular imaging.
The Johns Hopkins Small Animal Imaging Resource Program (SAIRP) works to generate the confidence necessary to move new cancer therapies to patients. Its ultimate goal is to move small animal imaging science forward to the point where the incorporation of such imaging techniques becomes second nature in the daily practice of cancer researchers.
Core Facility: Cancer Functional Imaging Core
Clinical Trial KeywordsAIDS, Dementia, MS, HIV, PSMA
Selected PublicationsView all on Pubmed
Banerjee, S.R., Pullambhatla, M., Byun, Y., Nimmagadda, S., Foss, C.A., Green, G., Fox, J.J., Lupold, S.E., Mease, R.C., Pomper, M.G. "Sequential SPECT and optical imaging of experimental models of prostate cancer with a dual modality inhibitor of the prostate-specific membrane antigen." Angew. Chem. Int. Edit. 2011, in press.
Bhang, H.-E., Gabrielson, K.L., Laterra, J., Fisher, P.B., Pomper, M.G. "Tumor-specific imaging through progression elevated gene-3 promoter-driven gene expression." Nat. Med. 17:123-129, 2011.
Banerjee, S.R., Pullambhatla, M., Byun, Y., Nimmagadda, S., Green, G., Fox, J.J., Horti, A., Mease ,R.C., Pomper, M.G. (68) "Ga-labeled inhibitors of Prostate-Specific Membrane Antigen (PSMA) for imaging prostate cancer." J. Med. Chem. 2010 Jun 22.
Nimmagadda, S., Pullambhatla, M., Stone, K., Green, G., Bhujwalla, Z.M., Pomper, M.G. "Molecular imaging of CXCR4 receptor expression in human cancer xenografts with [64Cu]AMD3100 positron emission tomography." Cancer Res. 70(10):3935-44, 2010.
Wang, H., Byun, Y., Barinka, C., Pullambhatla, M., Bhang, H.-E., Fox, J.J., Lubkowski, J., Mease, R.C., Pomper, M.G. "Bioisosterism of urea-based GCPII inhibitors: synthesis and structure-activity relationships." Bioorg. Med. Chem. Lett. 20(1):392-7, 2010.
Zhang, Y., Byun, Y., Ren, Y.R., Liu, J.O., Laterra, J., Pomper, M.G. "Identification of inhibitors of ABCG2 by a bioluminescence imaging-based high-throughput assay." Cancer Res. 69:5867-75, 2009.
Fu, D,, Tanhehco, Y., Chen, J., Foss, C.A., Fox, J.J., Chong, J.-M., Fukayama, M., Sgouros, G., Kowalski, J.,Pomper, M.G., Ambinder, R.F. "Bortezomib-induced enzyme-targeted radiotherapy in herpesvirus-associated tumors." Nat. Med. 14:1118-1122, 2008.
Diaz, L.A., Foss, C.A., Thornton, K., Nimmagadda, S., Endres, C.J., Uzuner, O., Seyler, T.M., Ulrich, S.D., Conway, J., Bettegowda, C., Agrawal, N., Cheong, I., Zhang, X., Ladenson, P.W., Vogelstein, B.N., Mont, M.A.,
Zhou, S., Kinzler, K.W., Vogelstein, B., Pomper, M.G. "Imaging of musculoskeletal bacterial infections by [124I]FIAU-PET/CT." PLoS One 2(10):e1007, 2007. Zhou, J., Neale, J.H., Pomper, M.G., Kozikowski, A.P. "NAAG peptidase inhibitors and their potential for diagnosis and therapy." Nat. Rev. Drug Discovery 4:1015-26, 2005.
Bettegowda, C., Foss, C.A., Wang, Y., Fox, J., Zhou, S., Kinzler, K., Vogelstein, B., Pomper, M.G. "Imaging bacterial infection in live animals with radiolabeled FIAU." Proc. Natl. Acad. Sci. USA 102:1145-51150, 2005.nt)
Labeled inhibitors of prostate specific membrane antigen (PSMA), biological evaluation, and use as imaging agents
Patent # US9044468 B2 | 06/02/2015
The prostate-specific membrane antigen (PSMA) is increasingly recognized as a viable target for imaging and therapy of cancer. Various 99mTc/Re-labeled compounds were prepared by attaching known Tc/Re chelating agents to an amino-functionalized PSMA inhibitor with or without a variable length linker moiety. Ex vivo biodistribution and in vivo imaging demonstrated the degree of specific binding to engineered PSMA+ PC3 PIP tumors.
Imaging infection with compounds that bind to thymidine kinase
Patent # US8691186 B2 | 04/08/2014
The instant invention provides a method for diagnosing an infection in a subject by administering to the subject a compound suitable for imaging which binds to a thymidine kinase present in the infecting organism, and obtaining an image of the subject to determine the presence and location of the compound, wherein a localization of the compound is indicative that the subject has an infection.
PSMA-binding agents and uses thereof
Patent # US8778305 B2 | 07/15/2014
Prostate-specific membrane antigen (PSMA) binding compounds having radioisotope substituents are described, as well as chemical precursors thereof. Compounds include pyridine containing compounds, compounds having phenylhydrazine structures, and acylated lysine compounds. The compounds allow ready incorporation of radionuclides for single photon emission computed tomography (SPECT) and positron emission tomography (PET) for imaging, for example, prostate cancer cells and angiogenesis.
TSPO-targeting compounds and uses thereof
Patent # US8778304 B2 | 07/15/2014
Translocator protein (TSPO) targeting compounds are described. Methods of making the compounds, and uses of the compounds for imaging are also described.
Imaging agents and methods of imaging NAALADase or PSMA
Patent # US8227634 B2 | 07/24/2012
The present invention relates to compounds particularly asymmetric urea compounds which are labeled with one or more radioisotopes and which are suitable for imaging or therapeutic treatment of tissues, organs, or tumors which express NAALADase and/or PSMA. In another embodiment, the invention relates to methods of imaging tissues, organs, or tumors using radiolabeled compounds of the invention, particularly tissues, organs, or tumors which express NAALADase and/or PSMA to which the compounds of the invention have an affinity.
Activities & Honors
- William R. Brody Professor of Radiology, 2011
- Johns Hopkins Vasculitis Center
- Neuropsychiatric Lupus, 2011
- Editor-in-chief, Molecular Imaging
- Past president of the Society, Nuclear Medicine's Molecular Imaging Center of Excellence